Vanguard Global Advisers
HOWL icon

Vanguard Global Advisers’s Werewolf Therapeutics HOWL Stock Holding History

Vanguard Global Advisers’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,343
Closed -$8.62K – 3688
2026
Q1 		$8.62K Buy
+10,343
New +$7.08K ﹤0.01% 3494

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Vanguard Global Advisers's HOWL Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Werewolf Therapeutics (HOWL) in Q2 2026, closing a stake of 10,343 shares — an estimated $8.62K sold.

Vanguard Global Advisers first reported a position in HOWL in Q1 2026 and held it in 1 quarter. The position peaked at $8.62K in Q1 2026. 42 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Werewolf Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 10,343 Werewolf Therapeutics shares in Q2 2026, an estimated $8.62K.
  • Vanguard Global Advisers first reported a position in Werewolf Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Werewolf Therapeutics position peaked at $8.62K in Q1 2026.
  • 42 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.